Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is well-positioned in the pharmaceutical market, with a diverse portfolio of products in immunology, oncology, and aesthetics, and a strong pipeline supported by recent acquisitions. The company shows promising growth potential, with strong TRx script growth in several key products and minimal impact from competitors in the near term. The company also demonstrates a commitment to sustainability and diversity, with formal governance structures in place to ensure responsible pricing decisions and promote diversity in leadership positions.

Bears say

AbbVie is facing multiple challenges as its core products, Humira, Skyrizi, and Rinvoq, experience pricing pressures and increased competition in the immunology segment. The recent IPR&D charge and acquisition of Allergan have also negatively impacted earnings and may not fully offset revenue decline from Humira's patent expiry. Upcoming catalysts, including clinical trial data and the planned Apogee acquisition, pose significant risks to the company's future performance, and the outlook remains uncertain.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $276.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $276.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.